The biosimilars industry is witnessing robust expansion driven by advancements in biopharmaceutical production and rising healthcare expenditure globally. Our analysis of the biosimilars market reveals significant growth potentials shaped by innovation, evolving regulatory frameworks, and increasing adoption across therapeutic areas. This blog presents a detailed biosimilars market size and report, covering segment dynamics, consumer behavior, competitive landscape, and strategic insights influencing market growth from 2025 to 2032.
The biosimilars market is estimated to be valued at USD 42.53 Bn in 2025 and is expected to reach USD 136.37 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 18.1% from 2025 to 2032.
Biosimilars Market Growth reflects rising demand for cost-effective biopharmaceutical alternatives and expanding applications in oncology, autoimmune disorders, and other therapeutic segments. Increasing market revenue stems from the gradual uptake of biosimilars in emerging economies, coupled with patent expirations of original biologics, further intensifying market trends favoring biosimilars adoption.
Biosimilars Market Segments
The biosimilars market is broadly segmented into product type, therapeutic application, and distribution channel.
- Product Type: Includes monoclonal antibodies, insulins, growth hormones, and hematopoietic agents. Monoclonal antibodies dominate this segment with over 40% revenue contribution in 2024, driven by biosimilars targeting oncology and immunology diseases. Growth hormones represent the fastest-growing sub-segment, registering a 22% CAGR, fueled by increasing pediatric and endocrine disorder treatments.
- Therapeutic Application: Comprises oncology, autoimmune diseases, and others such as cardiovascular and infectious diseases. Oncology holds the dominant position in 2024 due to rising cancer prevalence and biosimilar launch successes. Autoimmune diseases account for the most rapid growth, propelled by the increasing recognition of biosimilars in managing rheumatoid arthritis and psoriasis.
- Distribution Channel: Divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies lead the channel distribution due to wide administration of biologics in clinical settings, while online pharmacy channels are the fastest growing, with over 25% growth fueled by increased digital healthcare consumption among patients in 2025.
Market Drivers
A crucial market driver is the increasing patent expiry of originator biologics between 2024 and 2025, which creates significant market opportunities for biosimilars. For instance, key biologics like adalimumab and infliximab faced patent cliffs in 2024, enabling biosimilars to capture sizable market revenue, supported by regulatory approvals expediting market access. Furthermore, policy reforms allowing streamlined biosimilar market entry in the U.S. and Europe in 2024 resulted in accelerated product launches, underpinning strong market dynamics and business growth in the biosimilars industry.
Segment Analysis: Product Type
Focusing on product type, monoclonal antibodies dominated biosimilars market revenue in 2024, driven by the commercial success of biosimilars targeting trastuzumab and rituximab. For example, Samsung Bioepis and Celltrion Healthcare reported combined revenue exceeding USD 2.5 billion solely from monoclonal antibody biosimilars in 2024. Meanwhile, insulins are the fastest-growing sub-segment within biosimilars, expanding due to increasing diabetes prevalence worldwide and greater acceptance of biosimilar insulins post-regulatory approvals in multiple countries during 2025. Product innovations enhancing stability and delivery mechanisms have contributed to this growth trajectory.
Consumer Behaviour Insights
Recent consumer behaviour demonstrates a marked shift towards digital consumption habits, with a 30% increase in biosimilar prescriptions initiated through telemedicine platforms in 2025, indicating rising patient comfort with remote healthcare services. Pricing sensitivity remains significant, as a 2024 global patient survey revealed that 65% of biosimilar users preferred these due to substantially lower costs compared to originators. Additionally, customization trends are emerging where physicians prioritize biosimilars with patient-specific efficacy and safety profiles, supported by growing pharmacovigilance data, reflecting a more informed and selective buyer base in the biosimilars market.
Key Players
Prominent market players shaping the biosimilars landscape include Amgen Inc., Pfizer Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH, Celltrion Healthcare Co., Ltd., Biocon Limited, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Merck & Co., Inc., Biogen Idec Inc, Coherus BioSciences, and Stada Arzneimittel AG. Throughout 2024 and 2025, these market companies actively pursued new product launches, regional expansions, and capacity enhancements—for example, Pfizer launched multiple oncology biosimilars in 2024 contributing to a minimum 15% revenue increase, while Samsung Bioepis expanded manufacturing capabilities in South Korea to meet rising demand, solidifying their market position.
Key Winning Strategies Adopted by Market Players
One impactful strategy was Amgen Inc.'s launch of a comprehensive patient support program in 2025, integrating digital adherence tools and education modules, resulting in a 20% increase in biosimilar uptake in key markets. Another notable approach was Celltrion Healthcare’s investment in localized manufacturing units in Europe in 2024 to reduce lead times and costs, which enhanced their supply chain resilience and market responsiveness, contributing to sustained business growth. Furthermore, Sandoz International GmbH leveraged data analytics in 2025 to customize marketing efforts based on regional prescriber behavior, driving more effective market penetration and increasing biosimilars market revenue by over 12%.
FAQs on Biosimilars Market
1. Who are the dominant players in the biosimilars market?
Leading companies include Amgen Inc., Pfizer Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH, and Celltrion Healthcare Co., Ltd., all of which have strengthened portfolios and expanded manufacturing bases from 2024 to 2025.
2. What will be the size of the biosimilars market in the coming years?
The biosimilars market size is expected to grow from USD 42.53 billion in 2025 to USD 136.37 billion by 2032, reflecting a CAGR of 18% during this forecast period.
3. Which therapeutic application holds the largest growth opportunity?
While oncology remains dominant, autoimmune diseases present the fastest growth opportunity due to increasing indications and biosimilar approvals.
4. How will biosimilars market trends evolve over the next five years?
Market trends point toward increased digital adoption, price competitiveness, and expanded regulatory support, driving broader biosimilar usage across emerging and developed markets.
5. What are the competitive landscape and challenges in the biosimilars market?
The competitive landscape is robust, characterized by innovation and strategic expansions. Challenges include regulatory complexities and physician/patient acceptance barriers, which companies are progressively addressing via education and compliance efforts.
6. What go-to-market strategies are commonly adopted in the biosimilars market?
Common strategies involve new product launches, regional capacity expansions, patient support programs, and tailored marketing approaches based on real-time data analytics to boost biosimilar adoption rates.
Get More Insights On- Biosimilars Market
Get this Report in Japanese Language: バイオシミラー市場
Get this Report in Korean Language: 바이오시밀러 시장
Read More Articles Related to this Industry
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
0 comment